Adam Feuerstein articles over last 30 days

- articles last 30 days - articles per day
Mentioned in this news Places Companies People
2015/03/23 15:23
2015/03/23 15:23
4d
On Monday, Vertex disclosed some new phase IIb study results that raise concerns VX-661 may not be as potent as previously hoped. The new VX-661 data in cystic-fibrosis patients aren't bad, per se,...
2015/03/23 15:23
2015/03/23 15:23
Latest videos
2015/03/20 17:23
2015/03/20 17:23
7d
Not everyone believes BIIB037 is destined to become a blockbuster Alzheimer's drug. Earlier today, I heard from a buyside source who is always skeptical. He writes: "How many times must provocative...
2015/03/20 15:19
2015/03/20 15:19
7d
Analysts are loving the latest news out of Biogen. Here's the key result, from the release: "Treatment with aducanumab produced a dose- and time-dependent reduction of amyloid plaque in the brain....
2015/03/20 12:29
2015/03/20 12:29
7d
In Alzheimer's patients who carry the AopeE4 gene, which puts them at higher risk for the disease, the rate of ARIA was 43% and 55% for the middle and high dose of BIIB037. This led to treatment...
2015/03/20 12:29
2015/03/20 12:29
7d
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in...
2015/03/19 12:22
2015/03/19 12:22
8d
CRANBURY, NJ (TheStreet) -- Amicus Therapeutics(FOLD - Get Report) will seek accelerated approval in the U.S. for its Fabry disease therapy in the second half of the year -- sooner than many investors...
2015/03/18 14:58
2015/03/18 14:58
9d
In January 2014, a 41-year-old mother named April Moundzouris who had been diagnosed with amyotrophic lateral sclerosis, or Lou Gehrig's disease, blogged that she was responding well to treatment in a...
2015/03/18 14:22
2015/03/18 14:22
9d
On top of the $179 million in contractually obligated spending, MannKind has its own operating expenses. On its last call, the company forecast general and administrative and research and development...
2015/03/13 19:58
2015/03/13 19:58
13d
Biotech firm Neuralstem's stock sank by 37% Thursday, to $2.37 a share, after it reported disappointing results from a clinical trial. Published: March 13, 2015 - 3:13 pm In January 2014, a...
2015/03/13 13:22
2015/03/13 13:22
14d
I asked RBC Capital analyst Michael Yee for help answering this question. "Yeezus," as we like to call him, has a good ear for what professional biotech investors are thinking. "Genfit's stock is...
2015/03/12 16:29
2015/03/12 16:29
15d
Instead of disclosing the results from all 15 ALS patients enrolled in Neuralstem's phase II study of NSI-566, the company decided to only release a comparison between the patients who responded and...
2015/03/10 15:24
2015/03/10 15:24
17d
Since the inception of the Maxim ATM in July 2012, Hemispherx has sold more than 80 million shares of company stock for net proceeds of $41.13 million, according to SEC filings. Hemispherx set up the...
2015/03/09 12:22
2015/03/09 12:22
18d
The relative benefit observed in myelofibrosis patients treated with pacritinib was large enough to meet the primary endpoint of the study, CTI Biopharma said, although details were not provided. A...
2015/03/06 11:22
2015/03/06 11:22
21d
Before you buy a basket of these stocks and pre-order the Ferrari, I would keep in mind that investors are hating Abbvie for over-paying for Pharmacyclics. Abbvie shares are down 5% as I write this...
2015/03/05 15:22
2015/03/05 15:22
22d
AbbVie Buys Pharmacyclics for $21B to Get Half of Big Cancer Drug AbbVie announced it is buying cancer drug-maker Pharmacyclics for $21 billion. Through the deal, AbbVie will receive access to...
2015/03/04 18:23
2015/03/04 18:23
22d
Investor transparency would be well served by companies making public full versions of FDA Complete Response Letters, instead of just describing the contents. After that, I'd like to see more...
2015/03/03 17:26
2015/03/03 17:26
24d
LA JOLLA, Calif. (TheStreet) -- Obese Americans taking Orexigen Therapeutics'(OREX - Get Report) Contrave to lose weight cut their risk of having a heart attack, stroke or dying from heart disease by...
2015/03/02 15:22
2015/03/02 15:22
25d
CLEVELAND, Ohio (TheStreet) -- Athersys(ATHX - Get Report) found a partner willing to help develop its off-the-shelf stem cell therapy for stroke in Japan. The timing of the new partnership with...
2015/03/02 04:22
2015/03/02 04:22
25d
Amgen believes proving Kyprolis' superiority over Velcade in the second-line multiple myeloma treatment setting further justifies the $10.4 billion paid for Onyx Pharmaceuticals, the developer of the...
2015/02/27 11:22
2015/02/27 11:22
28d
Burt R. asks, "Can you talk about the impact of Breakthrough Therapy Designation on Celldex Therapeutics? I understand this is good news but less sure if it increases the chances for getting the...
2015/03/23 15:23
2015/03/23 15:23
Latest from Twitter